Equities Research Analysts’ Downgrades for May 24th (AINV, ARBK, ATNM, AVDX, AVXL, BIOC, BLBD, BOWL, BPMUF, BSFC)

Equities Research Analysts’ downgrades for Tuesday, May 24th:

Apollo Investment (NASDAQ:AINV) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Apollo Investment Corporation is a closed-end investment company that has elected to be treated as a business development company under the Investment Company Act of 1940. The Company’s investment portfolio will be principally in middle-market private companies. “

Argo Blockchain (NASDAQ:ARBK) was downgraded by analysts at Zacks Investment Research from a hold rating to a strong sell rating. According to Zacks, “Argo Blockchain Plc provides sustainable blockchain infrastructure and cryptocurrency mining. Argo Blockchain Plc is headquartered in London, UK. “

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium’s lead application for their ARCs is targeted conditioning, which is intended to selectively deplete a patient’s disease or cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, Gene Therapy or Adoptive Cell Therapy (ACT) such as CAR-T to enable engraftment of these transplanted cells with minimal toxicities. With their ARC approach, they seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently. Their lead product candidate, I-131 apamistamab (Iomab-B) is being studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The SI “

AvidXchange (NASDAQ:AVDX) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “AvidXchange Holdings Inc. is a provider of accounts payable automation software and payment solutions for middle market businesses and suppliers. The company’s software-as-a-service-based, end-to-end software and payment platform digitizes and automates the AP workflows for businesses and supplier. AvidXchange Holdings Inc. is based in CHARLOTTE, N.C. “

Anavex Life Sciences (NASDAQ:AVXL) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “ANAVEX LIFE SCIENCES CORP. is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases. The company’s proprietary SIGMACEPTOR Discovery Platform involves the rational drug design of compounds that fulfill specific criteria based on unmet market needs and new scientific advances. Selected drug candidates demonstrate high, non-exclusive affinity for sigma receptors, which are involved in the modulation of multiple cellular biochemical signaling pathways. “

Biocept (NASDAQ:BIOC) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for breast cancer. Biocept, Inc. is headquartered in San Diego, California. “

Blue Bird (NASDAQ:BLBD) was downgraded by analysts at Zacks Investment Research from a hold rating to a strong sell rating. According to Zacks, “Blue Bird Corp. is engaged in the designing, engineering, manufacturing and sale of school buses and related parts. It also offers alternative fuel applications with its propane-powered and compressed natural gas-powered school buses. Blue Bird Corp. is headquartered in Cambridge, Massachusetts. “

Bowlero (NYSE:BOWL) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Bowlero Corp. is an owner and operator of bowling centers as well as owner of the Professional Bowlers Association. Bowlero Corp., formerly known as Isos Acquisition Corporation, is based in RICHMOND, Va. “

Basilea Pharmaceutica (OTCMKTS:BPMUF) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Basilea Pharmaceutica Ltd. is a commercial stage biopharmaceutical company developing products that address the medical challenge of increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. “

Blue Star Foods (OTCMKTS:BSFC) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Blue Star Foods Corp. is an integrated ESG seafood company which processes, packages and sells seafood products. Blue Star Foods Corp. is based in Miami, Florida. “

BioSig Technologies (NASDAQ:BSGM) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals. The Company’s first product, PURE EP ™ System, is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory. “

Cabaletta Bio (NASDAQ:CABA) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Cabaletta Bio Inc. is a clinical stage biotechnology company. It is focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company’s product pipeline consists of DSG3-CAART, DSG3/1-CAART, MuSK-CAART and FVIII-CAART which are in clinical stage. Cabaletta Bio Inc. is based in Philadelphia, United States. “

Candel Therapeutics (NASDAQ:CADL) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Candel Therapeutics Inc. is a late clinical stage biopharmaceutical company. It involved in developing novel oncolytic viral immunotherapies. The company’s product pipeline includes CAN-2409 and CAN-3110. Candel Therapeutics Inc. is based in NEEDHAM, Mass. “

Centamin (OTCMKTS:CELTF) was downgraded by analysts at Zacks Investment Research from a buy rating to a sell rating. According to Zacks, “Centamin plc is a mineral exploration development and mining company. It engages in the exploration, mining and development of mineral properties primarily in Egypt, Ethiopia, the United Kingdom and Australia. The company’s current projects include Sukari old Mines and focuses on the Arabian-Nubian Shield. Centamin plc is headquartered in Saint Helier, Jersey. “

Receive News & Ratings for Apollo Investment Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Investment Co and related companies with MarketBeat.com's FREE daily email newsletter.